Skip to content
ppharmaranks
Menu
Cipla logo

abacavir, dolutegravir, lamivudine

Pharmaranks rates Abacavir, Dolutegravir, Lamivudine 3.5/5 for recall safety — an independent score from its FDA recall history and its manufacturer's record. Abacavir, Dolutegravir, Lamivudine is a medication supplied as a tablet.

Generic · by Cipla

70/100Limited · 1 source

Based on 1 source · Recall-safety score from FDA recall history — this product's own recalls and its manufacturer's record. Not an efficacy or quality rating. methodology →

Rated against independent regulatory sources·Last updated August 21, 2026·How we rate
Verified againstopenFDANIH DailyMedRxClass

Key facts

Form
Tablet
Strength
ABACAVIR, DOLUTEGRAVIR, Lamivudine 300MG · ABACAVIR, DOLUTEGRAVIR, Lamivudine 50MG
Type
Prescription (Rx)
Brand or generic
Generic
Manufacturer
Cipla
Half-life
about 14 hours (how long it stays in your system)
FDA application
ANDA210391
Availability
Discontinued (per FDA)

How long does Abacavir, Dolutegravir, Lamivudine stay in your body?

The elimination half-life of abacavir, dolutegravir, lamivudine is about 14 hours — the time it takes the body to clear about half of it. As a rule of thumb, a medicine is mostly gone after roughly 4 to 5 half-lives, though this varies from person to person with age and kidney or liver function. This is the terminal (elimination) half-life, which the TIVICAY label gives as "approximately 14 hours," based on population pharmacokinetic analyses; the label reports no separate distribution-phase half-life. Dolutegravir is not a prodrug, and the label describes no active metabolite — it is metabolized mainly by UGT1A1 (with some CYP3A) to an ether glucuronide and oxidative metabolites that the label does not characterize as active, and just over half the dose leaves unchanged in the feces. On populations the label names: age had no clinically relevant effect on dolutegravir pharmacokinetics; mild and moderate kidney impairment had no clinically relevant effect on exposure, and in severe kidney impairment (CrCl under 30 mL/min) exposure was actually lower, not higher (AUC down 40%), with too little information to recommend dosing in people on dialysis; in moderate liver impairment (Child-Pugh B) exposure was similar to healthy controls, and severe liver impairment (Child-Pugh C) has not been studied. The label frames these as changes in exposure rather than stating a revised half-life for each group. People with UGT1A1 genotypes conferring poor metabolism had 32% lower clearance and 46% higher AUC. This figure describes how long the drug itself is cleared from plasma — it is not a drug-test detection window (metabolites can be detected far longer) and not dosing guidance.

This is general information, not medical advice. It doesn’t tell you when a drug test would read negative (tests detect substances for different, often longer, windows) or when it’s safe to take another dose — ask your pharmacist or prescriber. Source: DailyMed — TIVICAY (dolutegravir sodium) tablet, film coated — Clinical Pharmacology (12.3).

Dosage forms

Tablet

The forms currently marketed in the U.S., per the FDA National Drug Code Directory.

Ways to save

Ask for the generic

Same active ingredient, far cheaper. Is there a generic? →

Request a 90-day supply

Bulk fills usually lower the per-dose price vs monthly refills.

Use copay cards

Manufacturer copay cards & patient-assistance programs — especially for brand drugs.

Compare alternatives

A same-class option may cost less. See alternatives →

Frequently asked questions

How is Abacavir, Dolutegravir, Lamivudine rated?
pharmaranks gives Abacavir, Dolutegravir, Lamivudine a composite score of 3.5 out of 5, currently based on 1 weighted source (FDA regulatory recall-safety data weighted highest). See our methodology at /how-we-rate.
Is there a coupon or discount for Abacavir, Dolutegravir, Lamivudine?
pharmaranks is an independent ratings site, not a pharmacy — we don't issue coupons or sell Abacavir, Dolutegravir, Lamivudine. To pay less, Abacavir, Dolutegravir, Lamivudine is already a generic — usually the lowest-cost version — so the main levers are comparing cash prices between pharmacies and using a pharmacy discount-card service. Prices vary by pharmacy, insurance, and location, so always confirm at the counter. This is general reference, not medical or financial advice.
Who makes Abacavir, Dolutegravir, Lamivudine?
Abacavir, Dolutegravir, Lamivudine is marketed by Cipla. You can see Cipla's full profile, rating, and other products on pharmaranks.
Is Abacavir, Dolutegravir, Lamivudine a brand-name or generic drug?
Abacavir, Dolutegravir, Lamivudine is a generic medication; its active ingredient is Abacavir, Dolutegravir, Lamivudine. Generics contain the same active ingredient as the brand-name original and are usually lower cost.
Is Abacavir, Dolutegravir, Lamivudine available over the counter?
No. Abacavir, Dolutegravir, Lamivudine is a prescription (Rx) medication in the US — you need a prescription from a licensed clinician (in person or via telehealth); it isn't sold over the counter. For some conditions there are OTC alternatives — ask your pharmacist.
What forms does Abacavir, Dolutegravir, Lamivudine come in?
Abacavir, Dolutegravir, Lamivudine is currently marketed as tablet, per the FDA's National Drug Code Directory.
Is Abacavir, Dolutegravir, Lamivudine FDA-registered?
Abacavir, Dolutegravir, Lamivudine is on record with the U.S. FDA under application number ANDA210391. You can verify this on its official FDA label.
Has Abacavir, Dolutegravir, Lamivudine been recalled by the FDA?
Abacavir, Dolutegravir, Lamivudine has no FDA recalls recorded under its own application in the openFDA enforcement database. Its recall-safety score reflects its manufacturer's overall recall record. This is general reference, not medical advice — check the FDA recall database for the latest alerts.
Is Abacavir, Dolutegravir, Lamivudine safe?
There's no single safe-or-not verdict. pharmaranks gives Abacavir, Dolutegravir, Lamivudine a recall-safety score of 70/100, based on its FDA recall history (no recalls under its own FDA application) — not an efficacy or side-effect rating. Review its FDA-label side effects and warnings before use, and always consult a licensed professional.

Information is sourced from public FDA regulatory data. Provided for general reference only — not medical advice. Always consult a licensed professional and the current prescribing information.

Reviews

No reviews yet. Be the first to write one.

Write a review

Reviews are user opinions, not medical advice. Consult a licensed professional.

People also viewed

Compare Abacavir, Dolutegravir, Lamivudine head-to-head

Identify a pill by its imprint →Check a drug interaction →Drug recalls →

Browse medications A–Z

Research products from A to Z, compare independent ratings, and find alternatives.

abacavir, dolutegravir, lamivudine

70/100